Method for producing human serum albumin

Abstract: A method for producing human serum albumin which comprises cultivation of a human serum albumin-producing host prepared by genetic engineering, in a medium containing a fatty acid having 10 to 26 carbon atoms or its salt, and a method for the cultivation of the host. HSA production can be greatly increased by the present invention.

Description: FIELD OF THE INVENTION The present invention relates to the improvement of the method for producing human serum albumin (hereinafter referred to as HSA), which comprises cultivation of a host transformed by genetic engineering, and the method for cultivating the host. BACKGROUND OF THE INVENTION HSA is a major component constituting protein in plasma, and has been used as a medicine for the treatment of, for example, massive bleeding, shocks, burn, hypoproteinosis, fetal erythroblastosis, and so on. At present, HSA is mainly produced as a product from fractions of collected blood. However, this production method is uneconomical and besides, the supply of the blood from which the HSA is produced is not always assured. Moreover, the blood can pose problems since it contains undesirable substances such as hepatitis virus. In recent years, production of various useful polypeptides by microorganisms or cells has become possible with the advent of recombinant DNA technology, and studies and developments of large-scale production of HSA by recombinant genetic engineering have been greatly made. However, the yield of HSA is low, and the industrial production technique which permits HSA production at a low cost with high purity remains to be established. SUMMARY OF THE INVENTION In view of the technical background as mentioned above, the present invention aims at increasing the production amount of HSA by way of the improvement of culture conditions. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a production method of HSA which comprises addition of a higher fatty acid having 10-26 carbon atoms or its salt in a culture medium when culturing an HSA-producing host prepared by genetic engineering. In this way, the production of HSA can be greatly increased. The present invention also relates to a method for culturing a host prepared by genetic engineering and capable of producing human serum albumin, which comprises culturing in a medium supplemented with a fatty acid having 10 to 26 carbon atoms or its salt. The HSA producing host to be used in the present invention which is prepared by genetic engineering is subject to no particular limitation as long as it is prepared by genetic engineering, and those disclosed in known literatures or those to be developed in the future can be appropriately used. Specific examples include fungi imparted with HSA producibility by genetic engineering such a s Escherichia coli , yeasts, Bacillus subtilis , etc., and animal cells. Particularly in the present invention, the use of a yeast, specifically the genus Saccharomyces or the genus Pichia as a host is desirable. Also, auxotroph strains or antibiotic sensitive strains can be used. In addition, the Saccharomyces cerevisiae AH22 strain or Pichia pastoris GTS115 strain can be preferably used. The method for the preparation of these HSA-producing hosts and the production method for HSA by the cultivation of a host, and the method for the separation and harvesting of HSA from cultures may be known methods or methods analogous thereto. For example, the methods for the preparation of HSA-producing host (or HSA-producing strain) include a method wherein a known human serum albumin gene is used (European Patent Publication Nos. 73646, 79739 and 206733), a method wherein a synthesized signal sequence is used (European Patent Publication No. 329127), a method wherein serum albumin signal sequence is used (European Patent Publication No. 319641), a method wherein a recombinant plasmid is incorporated on chromosome (European Patent Publication No. 399455), a method wherein hosts are fused (European Patent Publication No. 409156), a method wherein mutation is caused in a medium containing methanol, a method wherein variant AOX 2 promoter (obtained by modifying natural AOX 2 promoter, such as by partial deletion, substitution or addition of its base sequence to improve activity as a promoter) is used, a production of HSA with yeast (European Patent Publication Nos. 123544, 248637 and 251744), a production of HSA with Pichia (European Patent Publication No. 344459), and the like. Of the methods mentioned above, the method wherein mutation is caused in a medium containing methanol comprises the following steps. That is, a plasmid having a transcription unit where HSA is expressed under the control of AOX 1 promoter is introduced into a suitable host, preferably a Pichia yeast, specifically into an AOX 1 gene region of GTS115 strain (NRRL accession No. Y-15851) by a conventional method to obtain a transformant (see European Patent Publication No. 344459). This transformant shows poor growth in a medium containing methanol. Then, this transformant is grown in a medium containing methanol to cause mutation, and only viable strains are collected. The methanol concentration is about 0.0001-5%. The medium may be artificial or natural, and incubation is conducted at 15-40°C for 1-1000 hours. The methods for the cultivation of an HSA-producing host, namely, HSA production method, include a method wherein a fed batch is used besides the methods described in the above publications. The methods for the separation, harvesting, and purification of HSA include inactivation of protease by heat treatment (European Patent Application No. 420007) and the staining prohibition method comprising various chromatography treatments besides the methods described in the above publications. The medium to be used for the cultivation of a transformant host is a medium known in this field which has been supplemented with a fatty acid having 10-26 carbon atoms or its salt, and the cultivation is conducted by a conventional method. The medium may be synthesized or natural, with preference given to liquid medium. For example, a synthesized medium may contain various sugars as carbon sources, urea, ammonium salt, nitrate, etc. as nitrogen sources, various vitamins and nucleotide as micronutrients, and Mg, Ca, Fe, Na, K, Mn, Co, Cu, etc. as inorganic salts, and exemplified by YNB liquid medium (0.7% yeast nitrogen base (Difco), 2% glucose). Examples of the natural medium include YPD liquid medium (1% yeast extract (Difco), 2% Bacto-peptone (Difco), 2% glucose). The pH of the medium may be neutral, weak basic, or weak acidic. When the host utilizes methanol, a medium containing methanol can be used. In this case, the methanol concentration is about 0.01-5%. The incubation temperature is preferably 15-40°C (20-30°C for yeasts, and 20-37°C for bacteria). The incubation is conducted for about 1 to 1000 hours, by allowing to stand, shaking, or stirring, under aeration by batch culture, semibatch culture, or continuous culture. Preculture in advance of the culture is preferable, wherein used is, for example, YNB liquid medium or YPD liquid medium. The preculture is conducted for 10 to 100 hours at 30°C for yeasts and 37°C for bacteria. The fatty acid to be used in the present invention is exemplified by those having 10 to 26, preferably 14 to 20, more preferably 14 to 18 carbon atoms, such as saturated or unsaturated fatty acids (e.g. myristic acid, palmitic acid, palmitoleic acid, oleic acid, t-vaccenic acid, linoleic acid and arachidonic acid). As the salts of these fatty acids, exemplified are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt, and organic amine salts. The fatty acid is added to the medium at a concentration of about 0.005-0.4% (w/v), with preference given to 0.01-0.2%. When it is added at a concentration of less than 0.005%, desired effects cannot be obtained, and when added at a concentration of more than 0.4%, production may decrease. While the fatty acid is generally added to the medium in an appropriate amount before the initiation of the incubation, it may be added at the initial stage of the incubation. After the termination of the incubation, HSA can be separated and purified by a known method from culture filtrate, fungi or cells. The present invention is in detail described in the following by illustrating Examples. Example 1 1. Strain to be used : Pichia pastoris GCP101 PC4130 can be obtained by the replacement of the AOX 1 gene region of Pichia pastoris GTS115 (his 4) (NRRL Y-15851) with the fractions cleaved with Not 1 of plasmid pPGP1 having a transcription unit where HSA expresses under the control of AOX 1 promoter, by the method as described in European Patent Publication No. 344459. Due to the absence of the AOX 1 gene, this strain shows poor growth in a medium containing methanol as a carbon source (Mut- strain). PC4130 was inoculated into 3 ml of YPD medium (1% yeast extract, 2% Bacto-peptone, 2% glucose), and 24 hours later, it was inoculated into 50 ml of YPD medium at a concentration that made the initial OD 540 0.1. After incubation at 30°C for 3 days, it was inoculated into 50 ml of YPD medium at a concentration that made the initial OD 540 0.1. The same subculture was repeated every three days. At every subculture, the cells were diluted with sterilized water to make the cell concentration 10 7 cells/plate, and coated on a 2% MeOH-YNB w/o a. a. plate (0.7% yeast nitrogen base without amino acid, 2% methanol, 1.5% agar powder). After incubation at 30°C for 5 days, presence or absence of colonies was observed. Twenty colonies were formed on a 2% MeOH-YNB w/o a. a. plate which had been coated with cells after 12 days' subculture. Mut- strain hardly grew on this plate, but Mut+ strain could grow. That is, colony formation on this plate indicates increase of utilization of methanol, and that a strain converted to Mut+ could be obtained. One of the colonies formed was appropriately diluted with sterilized water, and expanded on a 2% MeOH-YNB w/o a. a. plate into single colony which was named GCP101. 2. Medium a) medium for preculture Bacto-Yeast Nitrogen Base (Difco, 6.7 g) was dissolved in water to make the entire amount 100 ml, and 10×YNB which was sterilized and filtered, 20% glucose which was sterilized in an autoclave, and sterilized water were mixed at the ratio of 1:1:8 (v) and used. b) medium for culture Various fatty acids as shown in Table 2 were added to a medium containing methanol and glycerol as carbon sources (Table 1), and used as a medium for the culture (pH 6.0). Component Concentration (1/ℓ) methanol 40 ml glycerol 1,000 mg ammonium acetate 5,000 mg KH 2 PO 4 10,000 mg CaCl 2 2H 2 O 100 mg KCl 2,000 mg NaCl 100 mg MgSO 4 7H 2 O 2,000 mg ZnSO 4 7H 2 O 100 mg CuSO 4 5H 2 O 5 mg FeCl 3 6H 2 O 100 mg biotin 0.1 mg vitamin B 1 10 mg vitamin B 6 1 mg pantothenic acid sodium 10 mg inositol 50 mg 3. Method of culture a) preculture One ml of 20% glycerol stored frozen in a vial was inoculated into 100 ml of YNB broth, and the broth was subjected to shaking culture in a 300 ml-Erlenmeyer flask equipped with a baffle at 30°C for 24 hours. b) culture After 100 ml of the preculture was subjected to centrifugal harvesting, it was suspended in 10 ml of sterilized water. The cell suspension (0.5 ml) was inoculated into 50 ml of the culture. The culture (50 ml) was dispensed to a 300 ml-Erlenmeyer flask equipped with a baffle, and subjected to shaking culture at 30°C and 125 rpm for 120 hours. The changes of HSA production amount and cell amount resulting from the cultivation in a medium containing a fatty acid are shown in Table 2. Additive Addition concentration (%, w/v) 0 0.01 0.05 0.1 Control 100/100 - - *a /*b myristic acid 100/100.6 200/100.6 palmitic acid 100/99.4 200/104.2 palmitoleic acid 100/77.3 200/111.3 oleic acid 200/103.0 200/103.6 200/108.9 t-vaccenic acid 150/89.7 200/85.6 linoleic acid 100/98.2 200/106.6 arachidonic acid 200/80.4 - sodium oleic acid 150/92.1 In the Table, *a shows relative values based on the HSA production of control (cultivation without fatty acid) which is taken as 100, and *b shows relative values based on the cell increase of control which is taken as 100. Measurement of HSA concentration The culture was sampled, and after 5 minutes' centrifugation at 15,000 rpm, the obtained culture supernatant was subjected to the measurement by reversed passive hemagglutination test (RPHA), and the HSA concentration in the sample was calculated from the comparison with the Standard HSA (Miles). Measurement of cell concentration The culture was sampled, and after appropriate dilution with distilled water, the absorbance at 540 nm was measured with spectrophotometer (Shimazu, UV 240). As has been described in the above, the present invention increases HSA production by cultivating a host obtained by genetic engineering, in a medium which has been added with a higher fatty acid having 10 to 26 carbon atoms or its salt. Example 2 Cultivation of Saccharomyces cerevisiae AH22 transformed and capable of secretory expression of human serum albumin Saccharomyces cerevisiae A124-35 (FERM BP-2527) was cultured in the following manner. A loopful of the above-mentioned recombinant yeast grown on a plate comprising 0.7% yeast nitrogen base, 2% glucose and 3% Bacto-agar was inoculated into 50 ml of YNB medium (0.7% yeast nitrogen base and 2% glucose) and cultured at 30°C for 2 days. The whole culture was then inoculated into 500 ml of YNB medium and cultured at 30°C for 2 days. Cells were collected by centrifugation, suspended in 500 ml of YPG medium (YPG was prepared by dissolving 10 g of yeast extract and 20 g of Bacto-peptone in water to make 900 ml. The solution was autoclaved and when cooled, mixed with 100 ml of separately autoclaved 20% galactose) with 0.1 w/v% oleic acid and shake-cultured at 30°C for 5 days. The HSA production multiplied 1.5 times that obtained by cultivation without oleic acid. Example 3 The Bacillus subtilis transformed and capable of secretory expression of human serum albumin (see European Patent Publication No. 229712) was cultured in 10 ml of 2% yeast extract (Gifco) containing 50 µg/ml erythromycin and 0.1 w/v% oleic acid at 37°C for 24 hours. The HSA production multiplied 2 times that obtained by cultivation without oleic acid. Example 4 Pichia pastoris GTS115 was transformed by mutant AOX 2 promoter obtained by modifying -255th base sequence of natural AOX 2 promoter [Yeast, vol. 5, 167-177 (1989)] from T to C, to obtain HSA-producing strain UHG42-3. This HSA-producing strain was inoculated into YPD medium, and cultured at 30°C overnight. The culture obtained was inoculated into 50 ml of 2% MeOH-YP medium (0.5% yeast extract, 2% Bacto-peptone, 2% MeOH) at a concentration that made the initial OD 540 0.1, and cultured at 30°C for 3 days. As a result, the HSA production with 0.1 w/v% oleic acid multiplied 1.2 times that obtained by cultivation without oleic acid.

Claims: A method for producing human serum albumin which comprises cultivating a human serum albumin-producing host prepared by genetic engineering in a medium containing a fatty acid having 10 to 26 carbon atoms or its salt. A method for producing human serum albumin according to Claim 1, wherein the fatty acid is added to the medium at a concentration of 0.005-0.4% (w/v). A method for producing human serum albumin according to Claim 1, wherein the fatty acid or its salt is selected from the group consisting of myristic acid, palmitic acid, palmitoleic acid, oleic acid, t-vaccenic acid, linoleic acid, arachidonic acid, and their salts. A method for producing human serum albumin according to Claim 1, wherein the human serum albumin-producing host is a fungus. A method for producing human serum albumin according to Claim 4, wherein the fungus is a yeast. A method for producing human serum albumin according to Claim 5, wherein the yeast is selected from the group consisting of the genus Saccharomyces and the genus Pichia . A method for producing human serum albumin according to Claim 1, wherein the medium is a liquid medium. A method for cultivating a human serum albumin-producing host prepared by genetic engineering, wherein the host is cultured in a medium added with a fatty acid having 10 to 26 carbon atoms or its salt.

Inventors: FUKUTSUKA HIROTOSHI, KOBAYASHI KAORU, KUWAE SHINOBU, OHMURA TAKAO, OHTANI WATARU, OOYA TOMOSHI, SUMI AKINORI, YOKOYAMA KAZUMASA, FUKUTSUKA, HIROTOSHI, KOBAYASHI, KAORU, KUWAE, SHINOBU, OHMURA, TAKAO, OHTANI, WATARU, OOYA, TOMOSHI, SUMI, AKINORI, YOKOYAMA, KAZUMASA, Fukutsuka, Hirotoshi, c/o The Green Cross Corp., Kobayashi, Kaoru, c/o The Green Cross Corp., Kuwae, Shinobu, c/o The Green Cross Corp., Ohmura, Takao, c/o The Green Cross Corp., Ohtani, Wataru, c/o The Green Cross Corp., Ooya, Tomoshi, c/o The Green Cross Corp., Sumi, Akinori, c/o The Green Cross Corp., YOKOYAMA, KAZUMASA, C/O THE GREEN CROSS CORP.
Applicants: GREEN CROSS CORP, THE GREEN CROSS CORPORATION
Application year: 1992
Main classification: C12N15
IPC codes: C12N1, C12N15, C12P21, C07K14, C12R1